99822-90-9Relevant academic research and scientific papers
NEW THERAPEUTIC USES OF COMPOUNDS
-
Paragraph 00285; 00286, (2021/10/02)
The present invention relates to the treatment and prevention of pulmonary inflammation using a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, and/or prodrug thereof. The pulmonary inflammation may be associated
IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS
-
Page/Page column 22; 23, (2016/04/10)
A compound as set out in claim 1, and the use of the same in therapy.
IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS
-
Page/Page column 28; 29, (2016/04/09)
A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.
IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
-
Page/Page column 25-26, (2014/09/29)
The compounds of formula (I) are inhibitors of semicarbazide- sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.
NEW COMPOUNDS
-
Paragraph 0212; 0122; 0123, (2014/09/29)
The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions w
N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: Cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism
Renard, Jean-Fran?ois,Lecomte, Frédéric,Hubert, Philippe,De Leval, Xavier,Pirotte, Bernard
, p. 12 - 22 (2014/02/14)
Nimesulide, a COX-2 preferential inhibitor with a favorable gastric and cardiovascular safety profile, was responsible for some cases of acute liver failure attributed to the nitrobenzene ring. A series of analogs of nimesulide resulting from isosteric replacement of the nitrobenzene ring by the pyridine nucleus, was synthesized and their ability to inhibit both cyclooxygenases (COXs) isoforms was evaluated in vitro using a human whole blood model. Compounds 19c, 23b and 23c displayed an important inhibitory activity associated to a COX-2/COX-1 selectivity ratio similar to or higher than that of celecoxib. The anti-inflammatory activity and the ability of several compounds to decrease leukocyte infiltration were further evaluated in vivo in a model of a λ carrageenan-induced pleurisy. Plasma assays were performed on blood samples collected from rats and allowed us to identify the 4-position of the phenyl ring as a major metabolism site explaining the occasionally observed lack of correlation between in vitro and in vivo results.
